If you ask me for a reason I'd buy Pfizer (NYSE: PFE) stock and never sell it, I certainly have one -- because I've already ...

PFE stock is up 11% in 2026, but flat guidance, falling COVID sales and patent cliffs cloud its rebound story. Buy, sell or hold?

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious about the stock’s prospects ...

Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive.

Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks under $50 to buy right now. Pfizer Inc. (NYSE:PFE) and Astellas Pharma ...

Morgan Stanley names Nvidia a top pick Morgan Stanley said it sees an attractive entry point. "For the last two quarters ...

Pfizer Inc. PFE shares are trending on Wednesday following the U.S. Food and Drug Administration’s (FDA) full approval of the BRAFTOVI combination regimen for treating metastatic colorectal cancer.

Pfizer (NYSE:PFE) received full FDA approval for BRAFTOVI (encorafenib) with cetuximab and fluorouracil-based chemotherapy as ...

Pfizer Inc. (NYSE:PFE) is one of the most undervalued stocks under $30 to buy. On February 24, the US FDA granted full ...

Richard Saperstein, Chief Investment Officer at Treasury Partner, joins CNBC's Halftime Report to detail his latest portfolio ...